Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy
Aspirin resistance describes a phenomenon where patients receiving aspirin therapy do not respond favorably to treatment, and is categorized by continued incidence of adverse cardiovascular events and/or the lack of reduced platelet reactivity. Studies demonstrate that one in four patients with vasc...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/19/11317 |
| _version_ | 1797479140325064704 |
|---|---|
| author | Hamzah Khan Omar Kanny Muzammil H. Syed Mohammad Qadura |
| author_facet | Hamzah Khan Omar Kanny Muzammil H. Syed Mohammad Qadura |
| author_sort | Hamzah Khan |
| collection | DOAJ |
| description | Aspirin resistance describes a phenomenon where patients receiving aspirin therapy do not respond favorably to treatment, and is categorized by continued incidence of adverse cardiovascular events and/or the lack of reduced platelet reactivity. Studies demonstrate that one in four patients with vascular disease are resistant to aspirin therapy, placing them at an almost four-fold increased risk of major adverse limb and adverse cardiovascular events. Despite the increased cardiovascular risk incurred by aspirin resistant patients, strategies to diagnose or overcome this resistance are yet to be clinically validated and integrated. Currently, five unique laboratory assays have shown promise for aspirin resistance testing: Light transmission aggregometry, Platelet Function Analyzer-100, Thromboelastography, Verify Now, and Platelet Works. Newer antiplatelet therapies such as Plavix and Ticagrelor have been tested as an alternative to overcome aspirin resistance (used both in combination with aspirin and alone) but have not proven to be superior to aspirin alone. A recent breakthrough discovery has demonstrated that rivaroxaban, an anticoagulant which functions by inhibiting active Factor X when taken in combination with aspirin, improves outcomes in patients with vascular disease. Current studies are determining how this new regime may benefit those who are considered aspirin resistant. |
| first_indexed | 2024-03-09T21:41:20Z |
| format | Article |
| id | doaj.art-ccf7c3bff49f411ebdff5ceec0acb406 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T21:41:20Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-ccf7c3bff49f411ebdff5ceec0acb4062023-11-23T20:31:03ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-09-0123191131710.3390/ijms231911317Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized TherapyHamzah Khan0Omar Kanny1Muzammil H. Syed2Mohammad Qadura3Division of Vascular Surgery, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaKeenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, ON M5B 1T8, CanadaDivision of Vascular Surgery, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaDivision of Vascular Surgery, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaAspirin resistance describes a phenomenon where patients receiving aspirin therapy do not respond favorably to treatment, and is categorized by continued incidence of adverse cardiovascular events and/or the lack of reduced platelet reactivity. Studies demonstrate that one in four patients with vascular disease are resistant to aspirin therapy, placing them at an almost four-fold increased risk of major adverse limb and adverse cardiovascular events. Despite the increased cardiovascular risk incurred by aspirin resistant patients, strategies to diagnose or overcome this resistance are yet to be clinically validated and integrated. Currently, five unique laboratory assays have shown promise for aspirin resistance testing: Light transmission aggregometry, Platelet Function Analyzer-100, Thromboelastography, Verify Now, and Platelet Works. Newer antiplatelet therapies such as Plavix and Ticagrelor have been tested as an alternative to overcome aspirin resistance (used both in combination with aspirin and alone) but have not proven to be superior to aspirin alone. A recent breakthrough discovery has demonstrated that rivaroxaban, an anticoagulant which functions by inhibiting active Factor X when taken in combination with aspirin, improves outcomes in patients with vascular disease. Current studies are determining how this new regime may benefit those who are considered aspirin resistant.https://www.mdpi.com/1422-0067/23/19/11317aspirinresistanceplateletaggregationpoint-of-careantiplatelet |
| spellingShingle | Hamzah Khan Omar Kanny Muzammil H. Syed Mohammad Qadura Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy International Journal of Molecular Sciences aspirin resistance platelet aggregation point-of-care antiplatelet |
| title | Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy |
| title_full | Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy |
| title_fullStr | Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy |
| title_full_unstemmed | Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy |
| title_short | Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy |
| title_sort | aspirin resistance in vascular disease a review highlighting the critical need for improved point of care testing and personalized therapy |
| topic | aspirin resistance platelet aggregation point-of-care antiplatelet |
| url | https://www.mdpi.com/1422-0067/23/19/11317 |
| work_keys_str_mv | AT hamzahkhan aspirinresistanceinvasculardiseaseareviewhighlightingthecriticalneedforimprovedpointofcaretestingandpersonalizedtherapy AT omarkanny aspirinresistanceinvasculardiseaseareviewhighlightingthecriticalneedforimprovedpointofcaretestingandpersonalizedtherapy AT muzammilhsyed aspirinresistanceinvasculardiseaseareviewhighlightingthecriticalneedforimprovedpointofcaretestingandpersonalizedtherapy AT mohammadqadura aspirinresistanceinvasculardiseaseareviewhighlightingthecriticalneedforimprovedpointofcaretestingandpersonalizedtherapy |